Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAgostinetto, Elisa
dc.contributor.authorHAMY, Anne-Sophie
dc.contributor.authorKim, Hwa Jung
dc.contributor.authorChiodi, Camila
dc.contributor.authorBruzzone, Marco
dc.contributor.authorBernstein Molho, Rinat
dc.contributor.authorCarrasco Lopez, Estela
dc.date.accessioned2024-10-30T09:53:08Z
dc.date.available2024-10-30T09:53:08Z
dc.date.issued2024-10
dc.identifier.citationAgostinetto E, Bruzzone M, Hamy AS, Kim HJ, Chiodi C, Bernstein-Molho R, et al. Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology. ESMO Open. 2024 Oct;9(10):103714.
dc.identifier.issn2059-7029
dc.identifier.urihttps://hdl.handle.net/11351/12154
dc.descriptionBRCA; Breast cancer; Histology
dc.description.abstractBackground Young women with breast cancer (BC) have an increased chance of carrying germline BRCA pathogenic variants (PVs). Limited data exist on the prognostic impact of tumor histology (i.e. ductal versus lobular) in hereditary breast cancer. Methods This multicenter retrospective cohort study included women aged ≤40 years with early-stage breast cancer diagnosed between January 2000 and December 2020 and known to carry germline PVs in BRCA1/2. Histology was locally assessed in each center. The Kaplan–Meier method and Cox regression analysis were used to assess disease-free survival and overall survival. Results Of 4628 patients included from 78 centers worldwide, 3969 (86%) had pure ductal, 135 (3%) pure lobular, and 524 (11%) other histologies. Compared with ductal tumors, lobular tumors were more often grade 1/2 (57.7% versus 22.1%), stage III (29.6% versus 18.5%), and luminal A-like (42.2% versus 12.2%). Lobular tumors were more often associated with BRCA2 PVs (71.1% BRCA2), while ductal tumors were more often associated with BRCA1 PVs (65.7% BRCA1). Patients with lobular tumors more often had mastectomy (68.9% versus 58.3%), and less often received chemotherapy (83.7% versus 92.9%). With a median follow-up of 7.8 years, no significant differences were observed in disease-free survival (adjusted hazard ratio 1.01, 95% confidence interval 0.74-1.37) or overall survival (hazard ratio 0.96, 95% confidence interval 0.62-1.50) between patients with ductal versus lobular tumors. No significant survival differences were observed according to specific BRCA gene, breast cancer subtype, or body mass index. Conclusions In this large global cohort of young BRCA carriers with breast cancer, the incidence of pure lobular histology was low and associated with higher disease stage at diagnosis, luminal-like disease and BRCA2 PVs. Histology did not appear to impact prognosis.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesESMO Open;9(10)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Aspectes genètics
dc.subjectMama - Càncer - Prognosi
dc.subjectHistologia
dc.subject.meshBreast Neoplasms
dc.subject.mesh/genetics
dc.subject.meshPrognosis
dc.subject.meshHistology
dc.titleCharacteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.esmoop.2024.103714
dc.subject.decsneoplasias de la mama
dc.subject.decs/genética
dc.subject.decspronóstico
dc.subject.decshistología
dc.relation.publishversionhttps://doi.org/10.1016/j.esmoop.2024.103714
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Agostinetto E] Academic Trials Promoting Team, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium. [Bruzzone M] U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. [Hamy AS] Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France. [Kim HJ] Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Chiodi C] Cancer Survivorship Program – Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France. [Bernstein-Molho R] Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center Affiliated to Tel Aviv University, Tel Hashomer, Israel. [Carrasco E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hereditary Cancer Genetics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid39288653
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record